Previous 10 | Next 10 |
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), filed its form 10Q for the period ending March 31 st , 2020. Within the report, the company showed a 77% net revenue increase from $0.7M in the prior quarter, to $1...
NEW HAVEN, Conn., May 12, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Quarter1-2020 corporate update call on Tuesday, May 19 th at 5:00 PM ET. The conference call may be accessed by calling 844-695-5519 ...
NEW HAVEN, Conn., April 06, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that it has launched its HemeScreen™ Reagent Rental (HSRR) program. The program enables Precipio to offer its patent-pending HemeScreen technology...
NEW HAVEN, Conn., March 20, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), released today the following letter to shareholders from its CEO, Ilan Danieli. Dear Shareholders, I’m writing this letter to you from my home office w...
DBV Technologies (NASDAQ: DBVT ) -50% on hiccup with Viaskin Peanut . More news on: DBV Technologies S.A., GNC Holdings, Inc., Sasol Limited, Stocks on the move, , Read more ...
NEW HAVEN, Conn., March 16, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that it has completed the non-cash transaction of the transition of Oncometrix’s customer base, as discussed in Precipio’s recent announc...
Groundbreaking clinical and economic impact to be generated NEW HAVEN, Conn., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that preliminary results from its artificial intelligence (AI) initial MVP (Minimal Viabl...
NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that it is in advanced discussions with Poplar Healthcare to establish a strategic partnership that includes, among other transactions, the acquisitio...
NEW YORK , Jan. 28, 2020 /PRNewswire/ -- TrialJectory , an AI-powered technology platform that empowers cancer patients to search and match with clinical trials, removing barriers to advanced treatment options, today announced that the Company has launched a new partnership with spe...
NEW HAVEN, Conn., Jan. 28, 2020 (GLOBE NEWSWIRE) -- The management team of Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), would like to provide an explanation on the recent Amendment to the S-1 that was filed yesterday, on January 27, 2020. The company filed its S-1...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to e...